ABBV vs DE: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Deere & Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
AbbVie Inc. · Healthcare
$197.69
+11.0% upside to fair value
Grade C
High Quality
VS
Deere & Company · Industrials
$578.39
+22.4% upside to fair value
Grade C
QuantHub Verdict
DE has more upside to fair value
(+22.4%).
DE trades at a lower forward P/E
(32.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
DE |
| Current Price |
$197.69 |
$578.39 |
| Fair Value Estimate |
$219.51 |
$708.19 |
| Upside to Fair Value |
+11.0%
|
+22.4%
|
| Market Cap |
$349.7B |
$156.2B |
| Forward P/E |
83.3x
|
32.5x
|
| EV / EBITDA |
23.4x
|
18.4x
|
| Price / Sales |
5.7x
|
3.4x
|
| Price / FCF |
18.7x
|
43.7x
|
| Revenue Growth YoY |
+10.0%
|
+16.3%
|
| Gross Margin |
70.2%
|
35.6%
|
| Operating Margin |
26.7%
|
18.5%
|
| Return on Equity |
-361.6%
|
18.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
2.29%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Deere & Company is a leading manufacturer of agricultural, construction, and forestry machinery, with a strong position in production and precision agriculture, small agriculture and turf, and construction and forestry segments. The company benefits from a durable competitive moat driven by its brand, intangible assets, and switching costs, supported by a CEO with deep institutional knowledge and…
Accumulation Zones
| Metric |
ABBV |
DE |
| Zone Low |
$164.63 |
$531.14 |
| Zone High |
$186.58 |
$601.96 |
| In Buy Zone? |
No
|
Yes
|